×
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
NASDAQ:JAZZ

Jazz Pharmaceuticals Stock Forecast, Price & News

$158.58
+2.57 (+1.65%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$153.96
$159.28
50-Day Range
$141.59
$166.14
52-Week Range
$117.64
$186.22
Volume
387,944 shs
Average Volume
589,968 shs
Market Capitalization
$9.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$204.14

Jazz Pharmaceuticals Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
28.8% Upside
$204.14 Price Target
Short Interest
Healthy
5.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.06mentions of Jazz Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$7.42 M Sold Last Quarter
Proj. Earnings Growth
8.15%
From $14.73 to $15.93 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.29 out of 5 stars

Medical Sector

188th out of 1,429 stocks

Pharmaceutical Preparations Industry

71st out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Jazz Pharmaceuticals logo

About Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

JAZZ Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
Employees
3,200
Year Founded
2003

Company Calendar

Last Earnings
5/04/2022
Today
7/01/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$204.14
High Stock Price Forecast
$225.00
Low Stock Price Forecast
$174.00
Forecasted Upside/Downside
+28.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81818181818182
Research Coverage
11 Analysts

Profitability

Net Income
$-329.67 million
Pretax Margin
-7.34%

Debt

Sales & Book Value

Annual Sales
$3.09 billion
Cash Flow
$23.70 per share
Book Value
$64.51 per share

Miscellaneous

Free Float
59,696,000
Market Cap
$9.90 billion
Optionable
Optionable
Beta
0.80

Social Links















Jazz Pharmaceuticals Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Jazz Pharmaceuticals stock.
View analyst ratings for Jazz Pharmaceuticals
or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price forecast for 2022?

11 brokerages have issued 12-month target prices for Jazz Pharmaceuticals' shares. Their JAZZ stock forecasts range from $174.00 to $225.00. On average, they predict Jazz Pharmaceuticals' share price to reach $204.14 in the next year. This suggests a possible upside of 28.7% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Jazz Pharmaceuticals' stock price performed in 2022?

Jazz Pharmaceuticals' stock was trading at $127.40 at the beginning of the year. Since then, JAZZ shares have increased by 24.5% and is now trading at $158.58.
View the best growth stocks for 2022 here
.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Jazz Pharmaceuticals
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its quarterly earnings results on Wednesday, May, 4th. The specialty pharmaceutical company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.13. The specialty pharmaceutical company earned $813.72 million during the quarter, compared to analyst estimates of $853.73 million. Jazz Pharmaceuticals had a negative net margin of 13.63% and a positive trailing twelve-month return on equity of 22.45%. The firm's quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.42 EPS.
View Jazz Pharmaceuticals' earnings history
.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.70 billion, compared to the consensus revenue estimate of $3.58 billion.

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the following people:
  • Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 58, Pay $2.27M) (LinkedIn Profile)
  • Mr. Daniel N. Swisher Jr., Pres (Age 59, Pay $1.27M)
  • Ms. Renee D. Gala, Exec. VP & CFO (Age 50, Pay $1.03M)
  • Mr. Christopher John Tovey BSc, Exec. VP, COO and MD of Europe & International (Age 57, Pay $880.61k)
  • Dr. Robert Iannone M.D., Exec. VP and Global Head of R&D (Age 55, Pay $983.25k)
  • Ms. Patricia Carr, Sr. VP & Chief Accounting Officer (Age 51) (LinkedIn Profile)
  • Dr. Finbar Larkin Ph.D., Sr. VP of Technical Operations (Age 64)
  • Ms. Andrea N. Flynn Ph.D., VP & Head of Investor Relations
  • Ms. Neena M. Patil J.D., Chief Legal Officer and Sr. VP of Legal & Corp. Affairs (Age 47) (LinkedIn Profile)
  • Dr. George Christopher Eliades Ph.D., Sr. VP of Corp. Devel. & Chief Transformation Officer (Age 52)

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $158.58.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.90 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329.67 million in net income (profit) each year or ($7.510010) on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals employs 3,200 workers across the globe.

Does Jazz Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More

When was Jazz Pharmaceuticals founded?

Jazz Pharmaceuticals was founded in 2003.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for Jazz Pharmaceuticals is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at [email protected], or via fax at 353-1634-7850.

This page (NASDAQ:JAZZ) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.